LENVATINIB
Manufacturer: Eisai Inc.
Score: 141.0
Lenvima (Lenvatinib) is a kinase inhibitor used for the treatment of various types of cancer, including differentiated thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma. It works by inhibiting certain enzymes involved in cancer cell growth and proliferation. The recommended dosage varies depending on the specific cancer type and patient population, and dose adjustments may be necessary based on individual patient tolerance and response. Lenvima can cause serious side effects, including hypertension, cardiac dysfunction, and hepatic impairment, and is contraindicated in patients with certain medical conditions. Special considerations are needed for use in pregnant women, nursing mothers, pediatric patients, and geriatric patients.
Lenvima can cause serious side effects, including hypertension, cardiac dysfunction, and hepatic impairment
Dose adjustments may be necessary based on individual patient tolerance and response
24 mg orally once daily
Not established
20 mg orally once daily in combination with pembrolizumab 200 mg intravenously every 3 weeks
Not established
12 mg orally once daily for patients ≥60 kg or 8 mg orally once daily for patients <60 kg
Not established
20 mg orally once daily in combination with pembrolizumab 200 mg intravenously every 3 weeks
Not established
PAZOPANIB
Teva Pharmaceuticals, Inc.
PAZOPANIB
Apotex Corp.
PAZOPANIB
AvKARE
PAZOPANIB
SUN PHARMACEUTICAL INDUSTRIES, INC.
PAZOPANIB
Golden State Medical Supply, Inc.
BINIMETINIB
Array BioPharma Inc.
RIBOCICLIB
Novartis Pharmaceuticals Corporation
FRUQUINTINIB
Takeda Pharmaceuticals America, Inc.